Kufe D W, Wick M M, Moschella S, Major P
Cancer. 1981 Oct 1;48(7):1513-6. doi: 10.1002/1097-0142(19811001)48:7<1513::aid-cncr2820480705>3.0.co;2-q.
The antitumor effect of thymidine has been demonstrated in patients with leukemia and lymphoma. This report summarizes the treatment of three patients with mycosis fungoides, a chronic T-cell lymphoma. Four courses of thymidine (75 g/m2/day) were administered by continuous infusion for 4-7 days. Steady-state serum thymidine levels were in the range of 1-3 mM. Associated toxicities were minimal and consisted of milk headache and anorexia. Myelosuppression was manifested by transient declines in the peripheral leukocyte count. One patient had extensive clearing of diffuse erythematous plaques on the trunk and extremities that persisted for over one month. A second patient had partial clearing of plaques that persisted for two weeks following therapy and a third patient had a minimal response with 25% reduction in lymphadenopathy and noduloulcerative lesions. These responses indicate the effectiveness of thymidine as a single agent in the treatment of mycosis fungoides.
胸苷对白血病和淋巴瘤患者的抗肿瘤作用已得到证实。本报告总结了3例蕈样肉芽肿（一种慢性T细胞淋巴瘤）患者的治疗情况。通过持续输注给予4个疗程的胸苷（75 g/m²/天），持续4 - 7天。稳态血清胸苷水平在1 - 3 mM范围内。相关毒性极小，包括乳酸性头痛和厌食。骨髓抑制表现为外周白细胞计数短暂下降。1例患者躯干和四肢广泛的弥漫性红斑斑块明显消退，持续超过1个月。第2例患者斑块部分消退，治疗后持续2周，第3例患者反应轻微，淋巴结病和结节溃疡性病变减少25%。这些反应表明胸苷作为单一药物治疗蕈样肉芽肿有效。
